Skip to main content
Erschienen in: International Urology and Nephrology 5/2015

01.05.2015 | Urology - Original Paper

Extraurothelial recurrence after radical nephroureterectomy: preoperative predictors and survival

verfasst von: Zoran Dzamic, Bogomir Milojevic, Boris Kajmakovic, Isidora Grozdic Milojevic, Nebojsa Bojanic, Sandra Sipetic Grujicic

Erschienen in: International Urology and Nephrology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

To identify the preoperative predictors of extraurothelial recurrence (EUR) after radical nephroureterectomy (RNU) in patients with upper tract urothelial carcinoma (UTUC).

Methods

A single-center series of 238 consecutive patients who were treated with RNU for UTUC was evaluated. Recurrence-free probabilities and cancer-specific survival (CSS) were estimated using the Kaplan–Meier method. Multivariate Cox proportional hazards regression models were used to evaluate the association between various clinicopathological factors and EUR.

Results

The median time to EUR was 17.6 months (range 3–73 months). EUR-free survival rates at 1, 3, 5, and 7 years were 87.8, 75.2, 73.5, and 72.6 %, respectively. In multivariate Cox regression analyses, tumor stage (HR 27.4; 95 % CI 7.83–95.8; p = 0.0001) and lymphovascular invasion (LVI) (HR 1.53; 95 % CI 1.22–3.12; p = 0.01) were independently associated with EUR. In patients with EUR, 5-year CSS estimate was 29.2 %. Tumor stage (HR 14.3; 95 % CI 4.55–45.2; p < 0.001) and EUR (HR 2.7; 95 % CI 1.54–4.73; p = 0.001) were the only independent predictors associated with worse CSS.

Conclusions

EUR significantly affected the prognosis in patients with UTUC managed by RNU. Patient with EUR had a greater probability of having higher tumor stages, higher tumor grades, and positive LVI. Tumor stage and LVI were independently associated with a worse EUR-free survival.
Literatur
1.
Zurück zum Zitat Jamal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130CrossRef Jamal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130CrossRef
2.
Zurück zum Zitat Raman JD, Scherr DS (2007) Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol 4:432–443CrossRefPubMed Raman JD, Scherr DS (2007) Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol 4:432–443CrossRefPubMed
3.
Zurück zum Zitat Margulis V, Youssef RF, Karakiewicz PI, Upper Tract Urothelial Carcinoma Group et al (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184:453–458CrossRefPubMed Margulis V, Youssef RF, Karakiewicz PI, Upper Tract Urothelial Carcinoma Group et al (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184:453–458CrossRefPubMed
4.
Zurück zum Zitat Favaretto RL, Shariat SF, Chade DC et al (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58:574–580CrossRefPubMedCentralPubMed Favaretto RL, Shariat SF, Chade DC et al (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58:574–580CrossRefPubMedCentralPubMed
5.
Zurück zum Zitat Leow JJ, Martin-Doyle W, Fay AP et al (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66(3):529–541CrossRefPubMed Leow JJ, Martin-Doyle W, Fay AP et al (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66(3):529–541CrossRefPubMed
6.
Zurück zum Zitat Chromecki TF, Cha EK, Fajkovic H et al (2012) The impact of tumor multifocalityon outcomes in patients treated with radical nephroureterectomy. Eur Urol 61:245–253CrossRefPubMed Chromecki TF, Cha EK, Fajkovic H et al (2012) The impact of tumor multifocalityon outcomes in patients treated with radical nephroureterectomy. Eur Urol 61:245–253CrossRefPubMed
7.
Zurück zum Zitat Fleming ID, Cooper JS, Henson DE et al (1997) Genitourinary site. In: Touhey R (ed) AJCC cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia, pp 231–246 Fleming ID, Cooper JS, Henson DE et al (1997) Genitourinary site. In: Touhey R (ed) AJCC cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia, pp 231–246
8.
Zurück zum Zitat Epstein JI, Amin MB, Reuter VR et al (1998) The World Health Organization/International Society of Urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22:1435–1448CrossRefPubMed Epstein JI, Amin MB, Reuter VR et al (1998) The World Health Organization/International Society of Urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22:1435–1448CrossRefPubMed
9.
Zurück zum Zitat Saito K, Kawakami S, Ohtsuka Y et al (2007) The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 100:269–273CrossRefPubMed Saito K, Kawakami S, Ohtsuka Y et al (2007) The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 100:269–273CrossRefPubMed
10.
Zurück zum Zitat Kikuchi E, Margulis V, Karakiewicz PI et al (2009) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27:612–618CrossRefPubMedCentralPubMed Kikuchi E, Margulis V, Karakiewicz PI et al (2009) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27:612–618CrossRefPubMedCentralPubMed
11.
Zurück zum Zitat Zigeuner R, Shariat SF, Margulis V et al (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57:575–581CrossRefPubMed Zigeuner R, Shariat SF, Margulis V et al (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57:575–581CrossRefPubMed
12.
Zurück zum Zitat Sundar SS, Ganesan TS (2007) Role of lymphangiogenesis in cancer. J Clin Oncol 25:4298–4307CrossRefPubMed Sundar SS, Ganesan TS (2007) Role of lymphangiogenesis in cancer. J Clin Oncol 25:4298–4307CrossRefPubMed
13.
Zurück zum Zitat Millikan R, Dinney C, Swanson D et al (2001) Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19:4005–4013PubMed Millikan R, Dinney C, Swanson D et al (2001) Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19:4005–4013PubMed
14.
Zurück zum Zitat Kunju LP, You L, Zhang Y et al (2008) Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 180:1928–1932CrossRefPubMed Kunju LP, You L, Zhang Y et al (2008) Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 180:1928–1932CrossRefPubMed
15.
Zurück zum Zitat Ku JH, Byun SS, Jeong H et al (2013) Lymphovascular invasion as a prognostic factor in the upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Eur J Cancer 49(12):2665–2680CrossRefPubMed Ku JH, Byun SS, Jeong H et al (2013) Lymphovascular invasion as a prognostic factor in the upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Eur J Cancer 49(12):2665–2680CrossRefPubMed
16.
Zurück zum Zitat Hurel S, Rouprêt M, Ouzzane A et al (2013) Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int 111(8):1199–1207CrossRefPubMed Hurel S, Rouprêt M, Ouzzane A et al (2013) Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int 111(8):1199–1207CrossRefPubMed
17.
Zurück zum Zitat Novara G, Matsumoto K, Kassouf W et al (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57(6):1064–1071CrossRefPubMed Novara G, Matsumoto K, Kassouf W et al (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57(6):1064–1071CrossRefPubMed
18.
Zurück zum Zitat Milojevic B, Djokic M, Sipetic-Grujicic S et al (2013) Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. Urol Oncol 31(8):1615–1620CrossRefPubMed Milojevic B, Djokic M, Sipetic-Grujicic S et al (2013) Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. Urol Oncol 31(8):1615–1620CrossRefPubMed
21.
Zurück zum Zitat Kwak C, Lee SE, Jeong IG et al (2006) Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 68:53–57CrossRefPubMed Kwak C, Lee SE, Jeong IG et al (2006) Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 68:53–57CrossRefPubMed
22.
Zurück zum Zitat Bamias A, Deliveliotis CH, Fountzilas G et al (2004) Adjuvant chemo-therapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol 22(11):2150–2154CrossRefPubMed Bamias A, Deliveliotis CH, Fountzilas G et al (2004) Adjuvant chemo-therapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol 22(11):2150–2154CrossRefPubMed
23.
Zurück zum Zitat Vassilakopoulou M, de la Motte Rouge T, Colin P et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a Large Multicenter Collaborative Study. Cancer 117:5500–5508CrossRefPubMed Vassilakopoulou M, de la Motte Rouge T, Colin P et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a Large Multicenter Collaborative Study. Cancer 117:5500–5508CrossRefPubMed
24.
Zurück zum Zitat Milenkovic-Petronic D, Milojevic B, Djokic M et al (2014) The impact of tumor size on outcomes in patients with upper urinary tract urothelial carcinoma. Int Urol Nephrol 46(3):563–569CrossRefPubMed Milenkovic-Petronic D, Milojevic B, Djokic M et al (2014) The impact of tumor size on outcomes in patients with upper urinary tract urothelial carcinoma. Int Urol Nephrol 46(3):563–569CrossRefPubMed
Metadaten
Titel
Extraurothelial recurrence after radical nephroureterectomy: preoperative predictors and survival
verfasst von
Zoran Dzamic
Bogomir Milojevic
Boris Kajmakovic
Isidora Grozdic Milojevic
Nebojsa Bojanic
Sandra Sipetic Grujicic
Publikationsdatum
01.05.2015
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 5/2015
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-015-0946-8

Weitere Artikel der Ausgabe 5/2015

International Urology and Nephrology 5/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.